MBD3L2 (methyl-CpG binding domain protein 3 like 2) is a chr19-associated protein that modulates transcriptional repression through interaction with the NuRD complex. Unlike its homologs MBD2 and MBD3, MBD3L2 lacks a functional methyl-CpG binding domain and does not directly bind methylated DNA 1. Instead, MBD3L2 interacts with MBD3 and core NuRD components (HDAC1, HDAC2, MTA1, p66, RbAp46/48), enabling it to displace the MeCP1 repressive complex from methylated DNA and potentially reactivate transcription 1. MBD3L2 also promotes Tet2 enzymatic activity in converting 5-methylcytosine to 5-hydroxymethylcytosine, more effectively than MBD3, thereby reducing methylation at promoter regions of cancer-related and metabolic genes 2. MBD3L2 expression is widespread across somatic tissues and germ cell tumors 3, with developmental stage-specific roles in trophectoderm specification and early tumor development 4, 5. Clinically, MBD3L2 serves as a salivary biomarker for pancreatic cancer detection, contributing to a predictive model achieving 90% sensitivity and 95% specificity 6, 7. Elevated MBD3L2 expression correlates with tumor aggressiveness and vascular/nerve infiltration 7, and its upregulation appears in facioscapulohumeral muscular dystrophy fetal development 8.